 This is an open-label, Phase I, dose-escalation study using a 3 3 design to assess the safety, tolerability, and pharmacokinetics of orally administered GDC-0941 administered QD. This study will include patients with locally advanced or metastatic solid tumors, NHL, or multiple myeloma MM expansion stage only for which standard therapy either does not exist or has proven ineffective or intolerable. 